An observational study in Type 2 Diabetes and Chronic Heart Failure, sponsored by Regionshospital Nordjylland. Recruiting at 1 site in Denmark. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-10.
Sponsored by Regionshospital Nordjylland · Observational
A cohort study on patients with type 2 diabetes to investigate possible biomarkers as predictors of chronic heart failure.
A cohort study on 500 patients with type 2 diabetes without known heart disease and age > 50 years of age. On inclusion and on yearly basis, patients are evaluated by echocardiography, ECG, blood tests to examine NT-ProBNP, hs-CRP, troponin, kidney function and 6 minutes hall walk test.
10,371 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,406 are open to participants now.
This study's planned enrollment of 500 is above the median of 300 across 1,741 observational studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Regionshospital Nordjylland is the lead sponsor of 18 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
500 patients with known type 2 diabetes who are treated at the department of endocrinology, North Denmark Regional Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Chronic Heart Failure
Determined by echocardiography according to European Society of Cardiology (ESC) definitions
Time frame: During 5 year follow up
NT-ProBNP
Change in N-terminal prohormone of brain natriuretic peptide (NT-ProBNP)
Time frame: During 5 year follow up
hs-CRP
Change in High-sensitivity C-reactive protein (hs-CRP)
Time frame: During 5 year follow up
Troponin
Change in Troponin
Time frame: During 5 year follow up
6 minutes walk test
Change in 6 minutes walk test
Time frame: During 5 year follow up
HOMA-IR
Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Time frame: During 5 year follow-up
Started Jul 2021 (actual). Primary completion is estimated for Jul 2027, 72 months after the start.
Of 432 non-industry observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 96. This study's planned 72 months is above that.
Counting every sponsor, half of 602 studies reached it within 32 months; a quarter within 17 and three quarters within 62.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Regionshospital Nordjylland